Telix Pharmaceuticals Limited (TLX)

NASDAQ: TLX · Real-Time Price · USD

9.47

-0.80 (-7.79%)

At close: May 22, 2026, 4:00 PM EDT

9.61

+0.14 (1.48%)

After-hours: May 22, 2026, 7:07 PM EDT

Telix Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	-	108.95	5.52
Revenue Growth (YoY)	-	-	-	1873.25%	37.53%
Cost of Revenue	-	-	-	-	1.85
Gross Profit	-	-	-	64.6	3.67
Selling, General & Admin	-	-	-	56.8	12.27
Research & Development	-	-	-	54.91	24.81
Other Operating Expenses	-	-	-	15.45	-
Total Operating Expenses	0	0	0	127.16	37.08
Operating Income	-	-	-	-62.56	-33.41
Interest Income	-	-	-	0	-
Interest Expense	-	-	-	-4.55	-3.79
Total Non-Operating Income (Expense)	-	-	-	-4.55	-3.79
Pretax Income	-	-	-	-67.11	-58.49
Provision for Income Taxes	-	-	-	-3.71	-0.03
Net Income	-	-	-	-70.83	-58.52
Net Income to Common	-	-	-	-70.83	-58.52
Shares Outstanding (Basic)	338	331	319	311	282
Shares Outstanding (Diluted)	338	345	324	311	282
Shares Change (YoY)	-2.12%	6.64%	4.21%	10.08%	9.69%
EPS (Basic)	-0.02	0.10	0.01	-0.23	-0.21
EPS (Diluted)	-0.02	0.10	0.01	-0.23	-0.21
EPS Growth	-	650.77%	-	-	-
Shares Outstanding	338.78	334.73	323.73	316.34	285.07
Free Cash Flow	-60.28	45.86	22.24	-48.32	-44.1
Free Cash Flow Growth	-	106.23%	-	-	-
Free Cash Flow Per Share	-0.18	0.13	0.07	-0.16	-0.16
Gross Margin	-	-	-	59.29%	66.46%
Operating Margin	-	-	-	-57.42%	-605.17%
Profit Margin	-	-	-	-65.01%	-1059.90%
FCF Margin	-	-	-	-44.35%	-798.67%
EBITDA	21.41	5.28	4.16	-58.9	-29.65
EBITDA Margin	-	-	-	-54.06%	-537.06%
EBIT	-	-	-	-62.56	-33.41
EBIT Margin	-	-	-	-57.42%	-605.17%
Effective Tax Rate	-	-	-	5.53%	0.06%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q